Milligan, G. (2023) GPR35: from enigma to therapeutic target. Trends in Pharmacological Sciences, 44(5), pp. 263-273. (doi: 10.1016/j.tips.2023.03.001) (PMID:37002007)
Text
294007.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 440kB |
Abstract
The orphan G-protein-coupled receptor 35 (GPR35), although poorly characterised, is attracting considerable interest as a therapeutic target. Marked differences in pharmacology between human and rodent orthologues of the receptor and a dearth of antagonists with affinity for mouse and rat GPR35 have previously restricted the use of preclinical disease models. The development of improved ligands, novel transgenic knock-in mouse lines, and detailed analysis of the disease relevance of single-nucleotide polymorphisms (SNPs) have greatly enhanced understanding of the key roles of GPR35 and have stimulated efforts towards disease-targeted proof-of-concept studies. In this opinion article, new information on the biology of the receptor is considered, whilst insight into how GPR35 is currently being assessed for therapeutic utility – in areas ranging from inflammatory bowel diseases to nonalcoholic steatohepatitis and various cancers – is also provided.
Item Type: | Articles |
---|---|
Additional Information: | This work is supported by grants from UKRI, Medical Research Council (grant number MR/X008827/1) and Biotechnology and Biosciences Research Council (grant number BB/P000649/1) to GM. |
Keywords: | G protein-coupled receptor, orphan receptor, kynurenic acid, fatty liver disease, inflammatory 14 bowel diseases, digestive system cancers. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Milligan, Professor Graeme |
Authors: | Milligan, G. |
College/School: | College of Medical Veterinary and Life Sciences > School of Molecular Biosciences |
Journal Name: | Trends in Pharmacological Sciences |
Publisher: | Elsevier (Cell Press) |
ISSN: | 0165-6147 |
ISSN (Online): | 1873-3735 |
Published Online: | 30 March 2023 |
Copyright Holders: | Copyright © 2023 Elsevier Ltd. |
First Published: | First published in Trends in Pharmacological Sciences 44(5): 263-273 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record